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Abstract
Background: Hypertension during pregnancy (HDP) increases the risk of future coronary heart disease (CHD),
but it is unknown whether this association is mediated by renal injury. Reduced renal function is both a
complication of HDP and a risk factor for CHD.
Methods: Logistic regression models were fit to examine the association between a history of HDP and the
presence and extent of coronary artery calcification (CAC), a measure of subclinical coronary artery athero-
sclerosis, in 498 women from the Epidemiology of Coronary Artery Calcification Study (mean age 63.3 9.3
years).
Results: Fifty-two (10.4%) women reported a history of HDP. After adjusting for age at time of study partici-
pation, HDP was associated with increased serum creatinine later in life ( p¼ 0.014). HDP was positively asso-
ciated with the presence of CAC after adjusting for age at time of study participation (OR¼ 2.7, 95% CI 1.4-5.4).
This association was slightly attenuated with adjustment for body size and blood pressure (OR¼ 2.4, 95% CI
1.2-4.9) but was not further attenuated with adjustment for serum creatinine and urinary albumin=creatinine
ratio (OR¼ 2.6, 95% CI 1.3-5.3). Results were similar for CAC extent.
Conclusions: HDP may increase a woman’s risk of future CHD beyond traditional risk factors and renal
function. Women with a history of HDP should be monitored for potential increased risk of CHD as they age.
Introduction
Hypertension during pregnancy (HDP), which in-cludes gestational hypertension, transient hypertension
of pregnancy, preeclampsia, and eclampsia, is the most
common complication of pregnancy, affecting 5%–10% of all
pregnancies in the United States.1 Women with HDP (without
preexisting hypertension) generally have resolution of their
elevated blood pressure (BP) following delivery of the fetus.2
There is increasing evidence, however, that a history of HDP
may have long-term implications for a woman’s health, in-
cluding an increased risk of hypertension3–5 and coronary
heart disease (CHD).6,7
Women who have experienced HDP are also at increased
risk for albuminuria,3,8 a future kidney biopsy,9 and devel-
opment of end-stage renal disease (ESRD).10 Preeclampsia
and eclampsia, two of the most severe types of HDP, are often
associated with a characteristic glomerular lesion, endo-
theliosis.11,12 Although delivery of the fetus is thought to re-
solve endotheliosis, there is increasing evidence that although
some cases completely resolve, other women who have ex-
perienced preeclampsia will go on to have evidence of longer-
term renal damage.13–15 Thus, we hypothesized that HDP
causes both renal injury and subtle coronary artery injury that
can eventually progress to detectable coronary artery disease
(CAD) and cardiac events.1,13,16,17 Even a subtle decrease in
renal function in women with a history of HDP may also
predict who is at risk of CHD.
Coronary artery calcification (CAC) is a marker of sub-
clinical coronary artery atherosclerosis. The extent of CAC
predicts the risk of CHD events.18–20 Albuminuria among
older (mean age 63 years)21 but not younger adults (mean age
44 years)22 and glomerular filtration rate (GFR)23 are each
associated with CAC presence and extent. Albuminuria is a
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potent predictor of future cardiovascular events, even among
persons with a normal GFR.24 Thus, it is of particular interest
whether variation in renal function explains the increased risk
of CHD in women with HDP.
We investigated whether a self-reported history of HDP,
using a validated survey,5 is associated with the presence and
extent of CAC in 498 non-Hispanic white women participat-
ing in the Epidemiology of Coronary Artery Calcification
(ECAC) Study, a community-based study in Rochester,
Minnesota. We further evaluated whether measures of renal
function, obtained at the same time as CAC measurement,




The Rochester Family Heart Study (RFHS), conducted
between 1984 and 1991, identified households where 2
children were enrolled in Rochester, Minnesota, schools. Iden-
tified household members, as well as other relatives, were
invited to participate in the RFHS; among the 3974 partici-
pants recruited into the RFHS, 2046 were females ranging in
age from 5 to 92 years.25,26 The ECAC Study, conducted be-
tween 1991 and 1998, examined 533 women 20 years of age
from the RFHS and 334 women 20 years of age living in the
vicinity of Rochester, who were not pregnant or lactating and
never had coronary or noncoronary heart surgery.27,28 Ques-
tions on reproductive history pertaining to HDP were asked
of the 574 (316 RFHS and 258 non-RFHS) women participat-
ing in the follow-up ECAC examination conducted between
December 2000 and February 2005. The present study is
limited to this follow-up examination.
A total of 563 non-Hispanic white women with informa-
tion on reproductive history had electron beam computed
tomography (EBCT) examinations to measure the presence
and extent of CAC. Twenty-nine women with prevalent CHD
(defined as self-reported history of myocardial infarction
[MI], stroke, or a positive angiogram), 10 missing risk factor
information, 1 who had kidney transplantation, and 25 with-
out a pregnancy lasting >6 months were excluded from
analyses. The final study group consisted of 498 (289 RFHS
and 209 non-RFHS) women. Study protocols were approved
by the Mayo Clinic and University of Michigan Institutional
Review Boards, and participants gave written informed
consent.
Risk factor assessment
During follow-up examination interviews, women were
asked about pregnancy history using a questionnaire5 re-
cently validated in a sample of women receiving care from the
Mayo Clinic in Rochester who experienced a pregnancy be-
tween 1960 and 1979 (average time since pregnancy was *27
years). This population is the same underlying population
sampled by the ECAC Study. Self-reported history of pre-
eclampsia, eclampsia, and toxemia was obtained from 103
women with a confirmed diagnosis of one of these conditions
and 100 women who had confirmed normotensive pregnan-
cies. Information gathered from the medical records was the
standard used for the diagnosis of preeclampsia and was used
to confirm the diagnosis based on current guidelines.2 Of the
103 women with preeclampsia, eclampsia, or toxemia, 82
(79.6%) recalled the diagnosis; only 4 (4%) participants with-
out a diagnosis of preeclampsia reported a history of these
conditions. Thus, the questionnaire used in the ECAC Study
has an estimated 80% sensitivity and 95% specificity.5 Women
in the ECAC Study with 1 pregnancy lasting >6 months
who reported high BP or hypertension during a pregnancy
(HDP) were considered to have HDP. Preeclampsia, eclamp-
sia, and toxemia were defined either by self-report of these
conditions or by self-report of protein in the urine during the
pregnancy with hypertension.
Participants reported current medication use and history
of smoking, physician-diagnosed hypertension, MI, angio-
graphic evidence of a blocked coronary artery, stroke, or
diabetes. Family history of premature CHD was defined as
self-reported MI or coronary artery revascularization in a
parent or sibling that occurred before age 60 years.29,30 Height
was measured by a wall stadiometer, weight was determined
by electronic balance, and body mass index (BMI) was cal-
culated. Waist circumference was measured at the umbilicus,
hips were measured at the level of maximal circumference,
and the waist=hip ratio was calculated.
Standard enzymatic methods were used to measure total
cholesterol, high-density lipoprotein cholesterol (HDL-C),
plasma glucose, triglycerides, and serum creatinine (SCr)
after overnight fasting.26 Low-density lipoprotein cholesterol
(LDL-C) was calculated using the Friedewald equation in
women with triglycerides<400 mg=dL.31 Systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP) levels were
measured three times at least 2 minutes apart in the right arm
with a random-zero sphygmomanometer (Hawksley and
Sons, Lancing, Sussex, UK). The average of the second and
third measurements was used. Pulse pressure (PP) was de-
fined as SBPDBP. Women were considered hypertensive if
they reported a prior diagnosis of hypertension and use of
prescription BP-lowering medication or if average SBP or DBP
was 140 mm Hg or 90 mm Hg, respectively. Women
were considered prehypertensive if their average SBP was
between 120 and 139 mm Hg or DBP was between 80 and
89 mm Hg and if they did not report a prior diagnosis of
hypertension or use of prescription BP-lowering medica-
tion.32 Participants were considered diabetic if they reported
using insulin or oral hypoglycemic agents or if they reported a
physician diagnosis of diabetes.
The first voided urine was collected on the morning of the
study visit and stored at808C until analyzed. Urine albumin
and urine creatinine concentrations were measured by stan-
dard methods on a Hitachi 911 Clinical Chemistry Analyzer
(Roche Diagnostics, Nutley, NJ). Urine albumin=urine creat-
inine ratio (UACR) was calculated and expressed as milli-
grams of albumin per gram of creatinine. Microalbuminuria
was defined as a UACR >30 mg=g.33 Estimated GFR (eGFR)
was calculated using the Modification of Diet in Renal Disease
equation that adjusts SCr for demographic variation (age,
sex, and race).34 Estimated GFR<60 mL=min per 1.73 m2 body
surface area was used to define women with GFR levels
consistent with chronic kidney disease.35
Measurement of CAC
CAC was measured with an Imatron C-150 EBCT scanner
(Imatron Inc., South San Francisco, CA).36 A scan run con-
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sisted of 40 contiguous 3-mm-thick tomographic slices from
the root of the aorta to the apex of the heart. Scan time was
100 ms=tomogram. Electrocardiographic gating was used,
and all images were triggered at end-diastole during 2–4
breath-holds. A radiological technologist scored the tomo-
grams with an automated scoring system without knowledge
of other EBCT examination results for the same participant.37
CAC was defined as a hyperattenuating focus within 5 mm of
the midline of a coronary artery, 4 contiguous pixels in size,
and having CT numbers >130 Hounsfield units throughout.
A score for each focus of CAC was calculated by multiplying
the focus area (square millimeters) by a density measurement
that was defined by the peak CT number in that focus.38 Total
CAC score was calculated as the sum of scores for all foci in
the epicardial arteries.38 Total CAC score was used to define
categories of CAC extent based on cutoff points previously
defined in women that are associated with increased risk of
MI (0, 1–10, 11–100, and>100).20 To reduce nonnormality, the
total CAC score was natural log transformed after adding 1.
Statistical methods
A statistical significance level of 0.05 was used. All tests
were two-sided. Our two selected measures of renal function,
SCr and UACR, were both nonnormally distributed, so each
measure was natural log-transformed (ln). Age-adjusted lin-
ear and logistic regression models (for continuous and dis-
crete variables, respectively) were fit to examine differences in
CHD risk factors and renal function measures between
women with and without reported HDP.
Logistic regression models were fit to examine the associ-
ation of HDP with CAC presence in the ECAC Study. We fit
an unadjusted model; a model adjusted for age; a model ad-
justed for age, waist=hip ratio, DBP, and SBP; and finally, a
model additionally adjusted for BMI, as done by others.39 We
then examined whether measures of renal function altered the
association of HDP with CAC presence by fitting a logis-
tic regression model additionally including ln(SCr) and
ln(UACR). The final model considered also included diabetes
status, menopause status, and BP-lowering medication use.
Two-way interactions between renal function measures and
all other model covariates were also considered.
Ordinal logistic regression models were fit to examine the
relationship between HDP and CAC extent (CAC score ca-
tegories of 0, 1–10, 11–100, and >100).20 The models allowed
estimation of the odds of being in a higher CAC score category
compared with a lower CAC score category. Models were fit
with the same risk factors and renal function measures as
described. The proportional odds assumption was tested with
the score test.
Results
Fifty-two women (10.4%) reported HDP. Of 50 women
with complete pregnancy data, 24 (48.0%) reported the HDP
was preeclampsia, eclampsia, or toxemia, and 21 (42.0%) re-
ported the HDP occurred during the first pregnancy. The
mean age of women with a history of HDP was significantly
less than among those without a history of HDP ( p¼ 0.026)
(Table 1).
Age-adjusted differences in CHD risk factors between
women with and without a history of HDP are presented in
Table 1. Women who reported a history of HDP had signifi-
cantly higher mean levels of SBP ( p¼ 0.006) and PP ( p¼ 0.002)
and a significantly higher frequency of hypertension
( p¼0.014), use of BP-lowering medications ( p¼ 0.020), and
diabetes ( p¼ 0.006) compared with women without HDP.
Relationship of HDP and CAC with renal function
Women with HDP had a significantly higher mean ln(SCr)
( p¼ 0.014) compared with women without HDP after ad-
justing for age; however, eGFR and ln(UACR) levels did not
differ between women with and without HDP ( p¼ 0.081 and
p¼ 0.974, respectively) (Table 1).
UACR levels differed significantly between women with
and without detectable CAC (mean standard deviation [SD]
UACR 13.3 52.7 vs. 4.6 9.5 mg=g, respectively; p¼ 0.004
on ln scale after age-adjustment). SCr levels did not signifi-
cantly differ between women with and without detectable
CAC (mean SCr 68.6 19.9 vs. 65.3 12.0 mmol=L, respec-
tively; p¼ 0.694 on ln scale after age-adjustment). eGFR levels
did not significantly differ between women with and without
detectable CAC (mean eGFR 86.2 25.4 vs. 89.3 19.2 mL=
min per 1.73 m2, respectively; p¼ 0.348 after age-adjustment).
Relationship of HDP with CAC presence
in ECAC Study
Table 2 shows the association of HDP, unadjusted and
adjusted for CHD risk factors, with CAC. HDP was signifi-
cantly associated with the presence of CAC after adjusting for
age and further adjustment for additional CHD risk factors.
Women with HDP had a 2.4 (95% confidence interval [CI] 1.2-
4.9) times greater odds of having detectable CAC ( p¼ 0.016)
than women without HDP after adjustment for selected CHD
risk factors.
Next, we examined whether the association between HDP
and CAC presence was explained by measures of renal func-
tion. After adjusting for ln(SCr) and ln(UACR), HDP remained
statistically significantly associated with CAC presence
( p¼ 0.010). In this model, a 1-unit increase in ln(UACR) was
associated with a 1.3 (95% CI 1.1-1.7) times increased odds of
having detectable CAC (data not shown). In this model,
ln(SCr) was not significantly associated with CAC presence
( p¼ 0.372) (data not shown). Finally, we further adjusted for
menopausal and diabetes status and use of BP-lowering
medication. In this model, HDP remained significantly asso-
ciated with CAC presence (OR¼ 2.2, 95% CI 1.0-4.6, p¼ 0.041).
There was no evidence of an interaction between HDP and
either measure of renal function with CAC presence.
Of the women with HDP, 24 (48.0%) had preeclampsia. We
compared CAC presence among three groups: those who had
a history of normotensive pregnancy, those with a history of
HDP (but not preeclampsia), and those with a history of pre-
eclampsia. Inferences were similar to inferences obtained when
women were dichotomized into those with and without HDP.
We also examined whether timing of HDP (in first pregnancy
or in a subsequent pregnancy) was associated with CAC
presence. Inferences were again similar; regardless of when the
HDP occurred, HDP was associated with CAC presence.
Relationship of HDP with CAC extent
The distribution of CAC extent (categories defined as CAC
score of 0, 1–10, 11–100, and >100) is shown in Table 1, and
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the association of HDP with CAC extent is shown in Table 3.
After adjusting for age, HDP was significantly associated with
CAC extent ( p¼ 0.002). After adjusting for age, BMI, waist=
hip ratio, DBP, and SBP, HDP continued to be significantly
associated with CAC extent ( p¼ 0.007). After further adjust-
ment for renal function measures, HDP remained signifi-
cantly associated with CAC extent ( p¼ 0.004). Women with
HDP had a 2.4 (95% CI 1.3-4.2) times greater odds of being in a
higher CAC extent category compared with women without
HDP. UACR was significantly associated with CAC extent
Table 1. Characteristics of 498 ECACa Study Women at Time of EBCT Examination, by HDP Statusb
Characteristic of women at time of examination Reported HDP No reported HDP pc
Number in group 52 (10.4%) 446 (89.6%) –
Age, years 60.6 10.6 63.6 9.1 0.026
Median age, years 61.0 63.2 –
(25th, 75th percentile) (38.3, 80.6) (33.8, 87.1) –
BMI (kg=m2) 30.1 6.4 28.5 5.9 0.135
Waist=hip ratio 0.87 0.10 0.86 0.10 0.335
SBP (mm Hg) 129.9 23.2 125.4 18.4 0.006
DBP (mm Hg) 69.8 10.9 68.9 9.1 0.623
PP (mm Hg) 60.1 20.4 56.5 15.6 0.002
Cholesterol (mmol=L) 5.3 0.8 5.3 0.9 0.698
HDL-C (mmol=L) 1.5 0.4 1.6 0.4 0.450
LDL-C (mmol=L)d 3.0 0.7 3.0 0.8 0.850
Triglycerides (mmol=L) 1.5 0.8 1.6 0.8 0.905
Fasting glucose (mmol=L) 5.6 1.3 5.5 1.1 0.185
Current smoker 6 (11.5%) 30 (6.7%) 0.409
Former smoker 22 (42.3%) 132 (29.6%) 0.073
Hypertension 29 (55.8%) 201 (45.1%) 0.014
Prehypertension 6 (11.5%) 82 (18.4%) 0.199
BP-lowering medications 28 (53.9%) 190 (42.6%) 0.020
Lipid-lowering medications 8 (15.4%) 116 (26.0%) 0.183
Diabetes 8 (15.4%) 27 (6.1%) 0.006
Family history of premature CHD 16 (30.8%) 141 (31.6%) 0.845
Number of pregnancies lasting >6 months 3.5 1.8 3.6 2.0 0.507
Postmenopausale 46 (88.5%) 408 (92.1%) 0.111
Hormone replacement usef 15 (32.6%) 137 (33.6%) 0.866
SCr (mmol=L) 72.5 24.5 66.5 15.7 –
Median SCR (mmol=L) 66.3 61.9 –
(25th, 75th percentile) (61.9, 81.8) (57.5, 75.1)
ln(SCr) 4.24 0.29 4.17 0.22 0.014
eGFR (mL=min per 1.73 m2) 84.3 27.8 87.9 22.3 0.081
Median eGFR (mL=min per 1.73 m2) 88.1 83.0 –
(25th, 75th percentile) (30.7, 165.8) (24.1, 175.8) –
eGFR <60 41 (9.2%) 9 (17.3%) 0.014
UACR (mg=g) 18.8 100.4 8.4 25.0 –
Median UACR (mg=g) 3.1 3.1 –
(25th, 75th percentile) (1.6, 5.4) (1.8, 5.2)
ln(UACR) 1.5 1.2 1.5 1.0 0.974
Microalbuminuria 22 (4.9%) 2 (3.9%) 0.817
CAC presence 35 (67.3%) 243 (54.5%) 0.004
Median CAC score 17.5 1.9 –
(25th, 75th percentile) (0.0, 131.2) (0.0, 81.4)
ln(CAC scoreþ1) 2.8 2.4 2.2 2.4 0.003
CAC score category 0.004
0 17 (32.7%) 203 (45.5%)
1–10 7 (13.5%) 44 (9.9%)
11–100 12 (23.1%) 106 (23.8%)
>100 16 (30.8%) 93 (20.9%)
aECAC, Epidemiology of Coronary Artery Calcification; EBCT, electron-beam computed tomography; HDP, hypertension during pregnancy;
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; BP, blood pressure; CHD, coronary heart disease; SCr, serum creatinine; ln, natural log;
eGFR, estimated glomerular filtration rate; UACR, urinary albumin creatinine ratio; CAC, coronary artery calcification; –, not tested.
bData are n (%) or mean SD or median (25th, 75th percentile).
cp value is for the age-adjusted difference between women with HDP and those without HDP (except for age) and is from linear regression
(continuous covariates) or logistic regression (discrete covariates).
dFive women (1 with HDP) missing LDL-C.
eThree women (all without reported HDP) missing menopause status information.
fAmong postmenopausal women.
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( p¼ 0.009); a 1-unit increase in ln(UACR) was associated with
a 1.3 (95% CI 1.1-1.5) times greater odds of being in a higher
rather than lower category of CAC extent after adjusting for
age, HDP, BMI, waist=hip ratio, SBP, DBP, and ln(SCr). In the
model, ln(SCr) was not significantly associated with CAC
extent ( p¼ 0.640). We further adjusted for menopausal and
diabetes status and BP-lowering medication use. In this
model, HDP remained significantly associated with CAC
extent (OR¼ 1.9, 95% CI 1.1-3.5, p¼ 0.032).
The proportional odds assumption was not rejected in any
model ( p> 0.1 for all models). There was no evidence of an
interaction between HDP and either measure of renal function
with CAC extent.
Inferences regarding association with CAC extent were the
same when we considered HDP as preeclampsia or no pre-
eclampsia and when we considered the timing of HDP (in first
pregnancy or in a subsequent pregnancy) (data not shown).
Discussion
In addition to providing evidence that HDP is a risk factor
for subclinical coronary artery atherosclerosis, our study
provides novel insight into understanding this risk factor as-
sociation with subclinical disease. We hypothesized that di-
minished renal function could account for the increased
presence and extent of subclinical coronary artery athero-
sclerosis associated with HDP. Instead, we found evidence
that HDP was associated with the presence and extent of
CAC, independent of renal function measures. Previously, a
significant association between HDP and the presence of
CAC was found in the Predictors of Response to Cardiac
Resynchronization Therapy (PROSPECT) Study; however,
PROSPECT did not investigate HDP’s association with CAC
extent nor were measures of renal function considered.39
Here, we have extended the findings from the PROSPECT
Study. In addition, the ECAC Study also had some informa-
tion on preeclampsia.
Preeclampsia, which may be a multisystem disease with
additional clinical presentations compared with the other
HDP disorders, may differentially influence future CHD
risk.40 In the ECAC Study, inferences remained the same
when we individually modeled preeclampsia or HDP without
preeclampsia compared with normotensive pregnancy, sug-
gesting that the spectrum of HDP, and not preeclampsia
alone, was associated with future subclinical coronary artery
atherosclerosis.
Neither our study nor the PROSPECT Study found an as-
sociation between fasting glucose level and HDP. A small
number of ECAC women (n¼ 35, 7%) had diabetes; after
adjusting for age, women with HDP were 2.7 (95% CI 1.4-5.4)
times more likely to have diabetes later in life than women
without HDP. Diabetes is a strong independent predictor of
CAC presence and extent41 and is the most common cause of
chronic kidney disease.42 After including diabetes status in
the final models in the present study, the association of HDP
with CAC presence and extent provided similar inferences as
before, although the odds ratio estimates were slightly at-
tenuated. HDP is associated with gestational diabetes,43 and
gestational diabetes is a risk factor for future development of
diabetes.44 We have no information on history of gestational
diabetes in the ECAC Study; thus, we cannot determine if this
attenuation of effect is due to HDP additionally capturing
some women with gestational diabetes. Future studies are
needed to assess the individual and joint effects of HDP and
gestational diabetes on future development of subclinical
coronary artery atherosclerosis.
We used SCR instead of eGFR in our models because the
study group was limited to white women, SCr measures were
age-adjusted, and a validated equation for the general pop-
ulation does not exist.45 However, inferences from models
using eGFR rather than SCR were the same.
Table 2. Association of HDP with Presence
of CAC in ECAC
a
Study
OR (95% CI) p
HDP unadjusted 1.72 (0.94-3.16) 0.081
HDP adjusted for age 2.72 (1.37-5.41) 0.004
HDP adjusted for age,
waist=hip ratio, SBP, DBP
2.43 (1.20-4.91) 0.013
HDP adjusted for age, BMI,
waist=hip ratio, SBP, DBP
2.41 (1.18-4.92) 0.016
HDP adjusted for age, BMI,
waist=hip ratio, SBP, DBP,
ln(SCr), ln(UACR)
2.58 (1.26-5.32) 0.010
HDP adjusted for age, BMI,





2.18 (1.03, 4.59) 0.041
aHDP, hypertension during pregnancy; CAC, coronary artery
calcification; ECAC, Epidemiology of Coronary Artery Calcification;
OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure;
DBP, diastolic blood pressure; BMI, body mass index; ln, natural log;
SCr, serum creatinine; UACR, urinary albumin creatinine ratio; BP,
blood pressure.
Table 3. Association of HDPa with Extent
of CAC, Defined Based on CAC Score Categories,
20
in ECAC Study
OR (95% CI) p
HDP unadjusted 1.62 (0.96-2.74) 0.069
HDP adjusted for age 2.50 (1.42-4.40) 0.002
HDP adjusted for age,
waist=hip ratio, SBP, DBP
2.23 (1.26-3.98) 0.006
HDP adjusted for age, BMI,
waist=hip ratio, SBP, DBP
2.22 (1.24-3.97) 0.007
HDP adjusted for age, BMI,
waist=hip ratio, SBP, DBP,
ln(SCr), ln(UACR)
2.36 (1.31-4.24) 0.004
HDP adjusted for age, BMI,






aHDP, hypertension during pregnancy; CAC, coronary artery
calcification; ECAC, Epidemiology of Coronary Artery Calcification;
OR, odds ratio; CI, confidence interval; SBP, systolic blood pressure;
DBP, diastolic blood pressure; BMI, body mass index; ln, natural log;
SCr, serum creatinine; UACR, urinary albumin creatinine ratio; BP,
blood pressure.
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In this sample of relatively older women, some may not
have accurately recalled history of HDP. Age was inversely
associated with HDP in the ECAC Study; this could indicate a
temporal trend in the diagnosis of HDP, a survival bias in that
older women with HDP died before inclusion in the ECAC
study, or a problem of recall bias. However, the questionnaire
used to define HDP has been validated in an independent
study.5 Similarly, in a recent study comparing self-reported
history of preeclampsia with diagnoses recorded in a hospital
discharge database (n¼ 2307 women), positive and negative
predictive values of self-reported preeclampsia were 59.2%
and 99.2%, respectively.46 It is more likely that women with
HDP would incorrectly self-report as not having HDP rather
than women without HDP self-reporting as having a positive
history of HDP; thus, associations would be biased toward the
null, and the strength of the relationship between HDP and
CAC may be underestimated in the present study.
We did not have information on when HDP occurred
during a pregnancy, whether or not the pregnancy was full-
term, or the birth weight of the baby. Women with pre-
existing, but undiagnosed, hypertension may have been
incorrectly diagnosed with HDP during their prenatal care, as
it may have been discovered for the first time during their
pregnancy. Thus, our definition of HDP may include women
who had chronic hypertension before their pregnancy. The
prevalence of hypertension among young, white women of
childbearing potential is rather low (6.2% among women
20–34 years of age and 16.5% among women 35–44 years of
age)47; thus, it is unlikely that many women were mis-
classified in the current study. Additionally, only 2 women
reported being diagnosed with hypertension prior to HDP.
Excluding these 2 women from the analyses did not alter the
inferences (data not shown).
The prevalence of detectable CAC was relatively high in the
current study (55.8%). The estimated odds ratio may over-
estimate the true relative risk of having detectable CAC under
the condition of high disease prevalence.48 Inferences from the
models (e.g., elevated risk of having detectable CAC presence
among women with HDP compared with women without
HDP), however remain the same whether using odds ratios or
relative risks to quantify the association.
Our study group was restricted to white, non-Hispanic
women, reflecting the population composition of the Roche-
ster, Minnesota, area at the time of the study. Rates of HDP
differ by race=ethnicity,49,50 and there are racial differences in
rates of hypertension,47 renal disease,42 and CAC burden.51
Our results are most generalizable to populations of white,
primarily postmenopausal, non-Hispanic women.
Although a direct relationship exists between CAC and both
histological and in vivo measures of atherosclerotic plaque on
a heart-by-heart, vessel-by-vessel, and segment-by-segment
basis,52–56 the absence of detectable CAC with EBCT does not
necessarily mean an absence of coronary artery atherosclerosis.
This measure likely underestimates total atherosclerosis in
some individuals because CAC more closely represents calci-
fied plaque burden than overall atherosclerosis.
Conclusions
Previous studies have shown an association between
traditional CHD risk factors measured early in life and
later subclinical coronary artery atherosclerosis and CHD
events.7,20,57–59 We have shown that HDP in early life predicts
future reduced renal function and increased presence and
extent of subclinical coronary artery atherosclerosis in older
women. Importantly, a history of HDP in early life was an
independent predictor of subclinical coronary artery athero-
sclerosis even after considering many traditional CHD risk
factors measured in later life. While women may commonly
delay focus on CHD health until midlife,54 education and
CHD risk factor monitoring may be especially important for
women with HDP, starting at postpartum checkups and
continuing across the life course, in order to reduce the CHD
burden in women.
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